- Research works
- 3 ▲ 117% vs 2013–17
- Citations
- 74 29.1 per fractional work
- Top-10% rate
- 0.0% record average 16.5%
- Open access
- 90% world 28%
Not ranked overall: Against Breast Cancer is under the volume floor below which an excellence rate is noise. Not ranked is not the same as ranked last.
Which research topics does Against Breast Cancer publish most on?
By volume in 2022–2025: BRCA gene mutations in cancer, PARP inhibition in cancer therapy, CRISPR and Genetic Engineering and Biomarkers in Disease Mechanisms.
Area is fractional works; colour is the subfield each topic belongs to.
- 1 BRCA gene mutations in cancer Genetics 0 works
- 2 PARP inhibition in cancer therapy Oncology 0 works
- 3 CRISPR and Genetic Engineering Molecular Biology 0 works
- 4 Biomarkers in Disease Mechanisms Immunology 0 works
- 5 Breast Cancer Treatment Studies Cancer Research 0 works
- 6 Cancer Cells and Metastasis Oncology 0 works
How open and international is its research?
Against the world’s own shares — the tick on each track. Both are shares of its output, so they sit on one scale and can be read against each other as well as against the world.
World: 28% of research is openly available.
World: 19% is written across borders.
How has Against Breast Cancer's research output changed?
Output in 2018–2022 was 117% higher than in 2013–2017.
The same series as a ribbon — one cell per year, darker for more. The line above answers how much; this answers when.
Other research institutions in Abingdon
- United Kingdom Atomic Energy Authority
- Culham Science Centre
- Culham Centre for Fusion Energy
- Oxford Instruments (United Kingdom)
- Evotec (United Kingdom)
- Summit (United Kingdom)
- Immunocore (United Kingdom)
- Tokamak Energy (United Kingdom)
Research measures only: rankings here say nothing about teaching, admissions or student experience. Comparable institutions and collaboration partners are in the interactive view on the map.